A fundamental transformation in healthcare was well underway when the COVID-19 pandemic struck. According to The Lancet Digital Health study from 2019, “deep learning offers considerable promise for medical diagnostics”. Then the rapidity of the spread of COVID-19, and the disease’s unique ability to root out our healthcare systems’ deepest failings, have medical experts looking for new solutions at a faster clip than ever before.
At Synaptiq we may be biased, but we believe artificial intelligence will play a prominent role in the future of healthcare. Why? To be effective, healthcare providers need access to accurate and timely information as well as effective treatments but also, critically, need time with patients. Unfortunately, time has become an increasingly rare commodity for doctors in recent decades. Re-humanizing healthcare requires, counterintuitively, reliance on a technology popularly thought to replace human workers.
Today’s medicine is data-rich and relies heavily on “knowledge workers” (in other words: a highly educated and specialized class of professionals) to deliver optimal results. AI will help bring about personalized and highly effective healthcare programs administered by doctors who can go back to the business of patient care. In essence, AI will be used to fill gaps humans cannot fill leaving humans to do what we do best.
Based on our work with healthcare solution providers and pharmaceutical companies, we see five critical ways AI will change the future of healthcare:
- Early detection and prevention
- Patient records and virtual care (check out our webinar on this).
- Alternative / holistic healthcare
- Drug discovery and development
- And, perhaps most hopefully, diagnostics and treatment
Next week we will focus on the future of AI and diagnostics and treatment specifically. On June 16 at 2pm ET, entrepreneurs on the front line of these transformational shifts in healthcare will join us for a BrightTALK panel discussion, moderated by our Chief Data Scientist, Tim Oates. We hope you will join us.
More about our panelists:
John P Alderete, PhD, is the Founder and President of Folium BioMed™ LLC, an investment and product development and evaluation company. He is currently the President and CEO of Aspis Health LLC and Apollos Diagnostics LLC, both Folium-owned medical device and diagnostics development companies based in Seattle, Washington. John has deep life sciences experience that includes basic and translational research, program management (both scientific and product level), product development, strategic and business development, technology assessment and development, fundraising and clinical trial design, implementation and data assessment. He has experience with medical devices, diagnostics, vaccines and therapeutics, with an emphasis in infectious diseases and oncology.
Brad Schmidt, PhD, is CEO of Panaxium, a bioelectronic medicine company pioneering precision treatment for neurological dysfunctions. Doctorate from Cornell University in Electrical and Computer Engineering as a member of Dr. Michal Lipson’s Nanophotonics Group, where Dr. Schmidt performed research in medical photonics and co-authored research in flexible electronics materials. Former McKinsey & Company management consultant. He is a member of the corporate board of Orthogonal Inc.
Jonathan Merril, MD, is the CEO of epitopeRX, a life-science company that is working to revolutionize the design, testing, and production of vaccines. EpitopeRX makes use of big-data analytics to rapidly design and evaluate vaccines . He has experience in machine learning as applied to the life sciences. He is a serial entrepreneur who has started and managed several companies directed to commercializing healthcare technology – all of which have resulted in acquisition or merger into public and private entities.